Press Releases Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
38.43 ^USD	-1.41%		-4.57%	+149.87%

May. 28	Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment	MT
May. 28	Vera Therapeutics Inc. Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors	Jun. 11	GL
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 07	GL
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 07	GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)	May. 28	GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)	May. 28	AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress	May. 25	AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress	May. 25	GL
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	May. 09	GL
Vera Therapeutics : Provides Business Update and Reports First Quarter 2024 Financial Results - Form 8-K	May. 09	PU
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 07	GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress	Apr. 02	GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress	Apr. 02	AQ
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 20	GL
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 20	AQ
Developing a new treatment paradigm for IgAN	Mar. 14	AQ
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference	Feb. 28	GL
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 02	GL
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock	Feb. 01	GL
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock	Jan. 29	GL
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock	Jan. 29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Press Releases

Filters